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Abstract
The cell surface mucin MUC1 is expressed by endometrial epithelial cells with increased abundance
in the secretory phase of the menstrual cycle, when it is found both at the apical cell surface and in
secretions. This suggests the presence of a maternal cell surface glycoprotein barrier to embryo
implantation, arising from the anti-adhesive property of MUC1. In previous work, we demonstrated
alternatively spliced MUC1 variant forms in tumour cells. The variant MUC1/SEC lacks the
transmembrane and cytoplasmic sequences found in the full-length variant. We now show that
MUC1/SEC mRNA is present in endometrial carcinoma cell lines, endometrial tissue and primary
cultured endometrial epithelial cells. The protein can be detected using isoform-specific antibodies
in uterine flushings, suggesting release from endometrium in vivo. However, on the basis of
immunolocalisation studies, MUC1/SEC also remains associated with the apical epithelial surface
both in tissue and in cultured cells. Transmembrane MUC1 and MUC1/SEC are both strikingly
localised to the apical surface of tubal epithelium. Thus MUC1 may contribute to the anti-adhesive
character of the tubal surface, inhibiting ectopic implantation. The mechanism by which this barrier
is overcome in endometrium at implantation is the subject of ongoing investigation.
Background
MUC1 is a high Mr, heavily glycosylated polymorphic
glycoprotein expressed in a variety of epithelia, including
the glandular and luminal epithelium of the endometri-
um [1–3]. It is encoded by a gene comprising 7 exons that
span approximately 4 to 7 kb of DNA, depending on the
number of 60 bp tandem repeat units within the variable
number of tandem repeats (VNTR) domain located in
exon 2 [1,4,5].
During the menstrual cycle the endometrium undergoes
cyclic phases of proliferation and differentiation. MUC1
expression is up-regulated in the secretory phase, and re-
mains high throughout the period of receptivity during
which embryo implantation occurs [6]. It is also elevated
in breast carcinoma relative to normal tissue [7] as well as
in the normal differentiated state of lactation [8].
Immunohistochemistry using monoclonal antibodies
(McAbs) to MUC1 core protein has shown that in
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proliferative phase endometrium, MUC1 is largely con-
fined to the apical surface of epithelial cells. The most well
characterised gene product is a type I integral membrane
glycoprotein (MUC1/REP/TM) [1,4,9]. However, in the
early secretory phase, increased intracellular MUC1 im-
munoreactivity reflects increased synthesis, the appear-
ance of specific glycoforms [10] and progressive
accumulation in glandular secretions. By the mid to late
secretory phase, abundant secretion of MUC1 occurs and
a soluble form can be detected in increasing amounts in
uterine fluid. At the same time however, significant
amounts of MUC1 remain associated with the apical epi-
thelial cell surface [3].
Two possible mechanisms have been proposed to account
for the production of soluble MUC1. It is known that a
proteolytic cleavage occurs during post-translational
processing of the cell-associated molecule within the en-
doplasmic reticulum [2]; the two resulting subunits re-
main non-covalently associated. The cleavage site has
been mapped to a site upstream of the transmembrane
domain [2,11,12]. The products are a large N-terminal
subunit containing the VNTR and a smaller C-terminal
subunit containing 58 residues of the extracellular do-
main, together with the transmembrane and cytoplasmic
domains. Release of the N-terminal subunit is thought to
occur due to dissociation of the complex or as a result of
a second cleavage. Evidence consistent with the release/
shedding of the N-terminal subunit has been obtained
from experiments in which full length MUC1 cDNA ex-
pression constructs were transfected into mouse cells [13].
MUC1 was identified in conditioned medium by radioim-
munoassay and immunoprecipitation using anti-VNTR
antibodies. Polyclonal antiserum against the cytoplasmic
tail failed to precipitate the soluble form, supporting the
hypothesis that release from the cell surface occurs either
as a result of proteolytic cleavage in the membrane-proxi-
mal domain or simple shedding of the N-terminal subu-
nit. Similar observations have been made in human
epithelial cell lines [14].
An alternative explanation for secreted MUC1 molecules
arose through the identification of a second MUC1 cDNA
species, MUC1/SEC [9]. This shares much of the MUC1/
REP/TM ectodomain, but 447 nucleotides distal to the
VNTR domain, MUC1/SEC becomes co-linear with ge-
nomic DNA because intronic sequences between exon 2
and exon 3 are not spliced out. The first 33 nucleotides of
the intron provide a short open reading frame with the ca-
pacity to encode a unique sequence of 11 amino acids.
This transcript contains a long 3' UTR. The predicted
translation product is a truncated form of MUC1 (MUC1/
SEC) that lacks the transmembrane and cytoplasmic do-
mains as well as the proteolytic cleavage site, and has the
potential to be secreted directly from the cell. Other splice
variants of the transmembrane form of MUC1 have also
been identified [15,16].
Most of the evidence for alternative splicing of MUC1 has
been obtained through work on breast carcinoma cell
lines and primary breast cancer tissue. It is interesting to
speculate whether the tissue type and state of differentia-
tion may affect the pattern of splicing. Indeed, loss of
MUC1/SEC expression has been associated with ovarian
malignancy [16]. In the current study, an analysis of
MUC1 alternative splicing in normal endometrial tissue
and endometrial carcinoma cell lines was performed us-
ing a reverse transcription polymerase chain reaction (RT-
PCR) strategy. Antibody reagents were used to verify trans-
lation from alternatively spliced transcripts in endometri-
al cell lines and tissue. Tubal tissue was also examined as
it contains a closely related epithelium with discrete func-
tions. The association of MUC1/SEC with the cell surface
in all tissues examined indicates that it contributes to the
glycocalyx of upper reproductive tract epithelia.
Materials and Methods
Cell lines
Endometrial carcinoma cell lines HEC1A (American type
culture collection, HTB-112) and HEC1B (HTB-113) were
obtained from Dr. Andrew Sharkey, University of Cam-
bridge. HEC1A cells were maintained in McCoy's 5a me-
dium (GibcoBRL) containing 10% foetal bovine serum
(FBS; Advanced Protein Products). HEC1B cells were
maintained in Eagle's MEM supplemented with Earle's
balanced salt solution, 10% FBS and 1 mM sodium pyru-
vate (GibcoBRL). The Ishikawa cell line was obtained
from Dr. John White, IRDB, Hammersmith Hospital, Lon-
don, and maintained in DMEM containing 20 mM HEPES
(GibcoBRL) and 10% FBS. The human breast carcinoma
cell line T47D was obtained from Dr. Michael Daws, Uni-
versity of Newcastle Upon Tyne. Cells were maintained in
DMEM containing 10% FBS and 1 µg/ml insulin. In addi-
tion, all media were supplemented with glutamine (2
mM; ICN) and antibiotics: streptomycin (100 µg/ml;
Evans Medical Ltd) and gentamycin (5 µg/ml; David Bull
Laboratories).
Uterine flushings
Uterine flushing was performed as an out-patient proce-
dure at the gynaecology clinic of the Jessop Hospital for
Women, Sheffield under local ethical committee approv-
al. The procedure and collection criteria were as previous-
ly described [3,17].
Endometrial primary culture
Endometrial epithelial cells (EEC) were grown from iso-
lated endometrial glands purified as previously described
[18,19]. Cells were cultured and grown to confluence in
steroid-depleted medium: 75% DMEM (Sigma, St. Louis,Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/2
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MO) and 25% MCDB-105 (Sigma) containing antibiot-
ics, supplemented with 10% charcoal-Dextran treated FBS
(Hyclone, Logan, UT) and 5 µg/ml insulin (Sigma) as de-
scribed [18].
Endometrial tissue and cell monolayer RNA extraction
Endometrial biopsy material obtained at dilatation and
curettage under local ethical committee approval was col-
lected directly into 2 ml guanidinium thiocyanate solu-
tion (4 M guanidinium thiocyanate, 0.5% N-
lauroylsarcosine, 0.1 M 2-mercaptoethanol, 0.1% Anti-
foam A and 25 mM sodium citrate pH 7.0) and homoge-
nised with a Polytron X-1020 (Brinkmann Instruments).
Denatured, homogenised samples were stored at -80°C
prior to RNA extraction. Cells were grown to confluence in
75 cm2 culture flasks (Falcon). Medium was removed and
cells washed 3 times in ice-cold PBS (pH 7.4). Guanidin-
ium thiocyanate solution (5 ml) was added to the flasks,
which were agitated for approximately 2 min. This solu-
tion was then transferred into a 50 ml universal (Falcon)
and stored as above. Total RNA was isolated using the acid
guanidinium thiocyanate-phenol-chloroform method
[20].
Purification of mRNA from total RNA
Poly (A+) RNA was purified from total RNA using pre-pre-
pared oligo d(T)-cellulose spin columns (mRNA Purifica-
tion Kit, Pharmacia Biotech) as directed by the
manufacturer. Briefly, total RNA sample was dissolved in
elution buffer (10 mM Tris-HCl (pH 7.4), 1 mM EDTA)
and heated to 65°C for 5 min. After rapid cooling on ice,
a 200 µl aliquot of sample buffer (10 mM Tris-HCl (pH
7.4), 1 mM EDTA, 3 M NaCl) was added to the RNA sam-
ple, which was then applied to the oligo d(T)-cellulose
column, pre-equilibrated with high salt buffer (10 mM
Tris-HCl; pH 7.4, 1 mM EDTA, 0.5 M NaCl). After the
sample had entered the cellulose matrix, the column was
spun at 350 g for 2 min. Two washes with high salt buffer
followed by two washes in low salt buffer (10 mM Tris-
HCl (pH 7.4), 1 mM EDTA, 0.1 M NaCl) were performed
before elution of bound poly (A)+ RNA was effected by the
application of four 250 µl aliquots of elution buffer, pre-
warmed to 65°C. For the analysis of alternative splicing it
was important to eliminate genomic DNA. To this end,
two rounds of column purification of poly(A)+ RNA were
performed.
First strand cDNA synthesis
Reactions were performed in a volume of 20 µl which con-
tained 10 µg of total RNA, diluted to a total volume of 8
µl in DEPC-treated water or 8 µl of oligo d(T)-cellulose
column eluate containing poly (A+). Samples were heated
to 65°C for 10 min and rapidly cooled on ice for 10 min.
The following reagents were then added sequentially: 4 µl
5 × RNA buffer (GibcoBRL; 250 mM Tris/HCl pH 8.3 at
room temperature, 375 mM KCl, 15 mM MgCl2), 2 µl 0.1
M DTT (GibcoBRL), 2 µl 4 mM (0.05 µg/µl) oligo d(T)
primer (16–28 nucleotides; Pharmacia Biotech), 2 µl 10
mM of each dNTP (40 mM total; a 1/10 dilution 0f 100
mM stock dNTP's, 8 µl of each dNTP in 48 µl of DEPC-
treated water; Pharmacia Biotech), 1 µl (30 units) RNA
Guard (Pharmacia Biotech) and finally 1 µl (200 units)
Moloney Murine Leukaemia Virus reverse transcriptase
(RT; GibcoBRL). The reaction was incubated at 37°C for 1
hour and then terminated by incubation at 75°C for 10
min in order to denature RT. After centrifugation for 1
min at 13,000 rpm in an MSE microfuge the reaction mix-
ture was stored at -80°C.
Primers to identify a MUC1/REP/TM transcript
The complete mRNA sequence of human polymorphic
epithelial mucin (MUC1) (GenBank J05581) was used to
design a primer pair for the identification of MUC1 tran-
scripts encoding a transmembrane domain. The upstream
primer 5'-AGC ACC GAC TAC TAC CAA G-3' (primer 1 in
Fig. 1B) hybridises at position 916 of J05581. The down-
stream primer 5'-CTG AGA AGT GTC CGA GAA A-3'
(primer 2 in Fig 1B) hybridises at position 1649. This
primer pair annealed at 55°C to generate a product of 752
bp.
Primers to identify a MUC1/SEC transcript
An upstream primer was designed using the mRNA se-
quence of human secreted epithelial tumour mucin anti-
gen (MUC1; GenBank accession number X52228). Primer
4 in Fig. 1A, 5'-TGG AGA CAC AGT TCA ATC AGT AT-3'
hybridises at position 1436 in exon 4. The downstream
primer (3 in Fig. 1A), 5'-TGC TCA CTT CAC GCC ACT T-
3' hybridises at position 3209 of Genbank sequence
M35093 (MUC1/SEC). This primer pair annealed at 57°C
to generate a product of 686 bp. Genomic DNA was not
amplified under the conditions used.
Primers required for specific sequence amplification
Primers were designed to enable amplification of intron
VI sequence from MUC1. The upstream primer 5'-AAG
TGG CGT GAA GTG AGC A-3' hybridises at position 3302
of Genbank sequence M61170, while the downstream
primer 5'-GCC TCT GGG TGC AAA AAA-3' hybridises at
position 3521. This primer pair anneals at 56°C to gener-
ate a product of 237 bp.
Polymerase Chain Reaction (PCR)
PCR's were carried out in 20 µl reaction volumes. Each re-
action contained: 2 µl each of the forward and reverse
primers (both at 5 µM), 2 µl 10 × PCR buffer (0.85 mg/ml
BSA, 670 mM Tris/HCl pH 9.0 at 25°C, 166 mM ammo-
nium sulphate and 1% Triton-X100), 1.5 µl 25 mM
MgCl2, 3.0 µl 2 mM dNTP mixture (each at 2 mM), 0.1 µl
of 10 units/µl TAQ DNA polymerase (0.5 units; Promega)Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/2
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and 7.4 µl sterile ultra-pure water to increase the reaction
volume to 18 µl. The reaction mixture was overlaid with
liquid paraffin to avoid evaporation of components dur-
ing thermal cycling. Finally, 2 µl of RT reaction mixture
containing cDNA (~1 µg) was added and contents of the
reaction vessel centrifuged before thermal cycling. Ampli-
fication reactions were performed in a Microprocessor
Controlled Incubation System (Appligene). Negative con-
trols in which cDNA was replaced by sterile ultra-pure wa-
ter were included in every series of reactions to ensure that
reagents were free from contaminating DNA. Thermal cy-
cling conditions were 95°C for 2 min, 35 cycles of 95°C
for 1 min, primer annealing for 1 min at the described
temperatures, 72°C for 1 min and a final 72°C incuba-
tion for 5 min.
PCR reactions were analysed by electrophoresis through
gels of 1% (w/v) agarose (Molecular biology grade, Sig-
ma) in 1 × Tris/acetate EDTA (TAE; 40 mM Tris, 21 mM
glacial acetic acid, 5 mM sodium EDTA) containing 0.5
µg/ml ethidium bromide. DNA was visualised by ethid-
ium bromide fluorescence on exposure to ultra-violet
light. Inclusion of a DNA 100 bp ladder (Pharmacia Bio-
tech) enabled sizing of PCR products.
Products were purified for restriction analysis and for use
as templates in subsequent PCR reactions. When a single
product was generated by PCR it was purified by chloro-
form extraction and ethanol precipitation. However,
when multiple products were generated electrophoretic
separation was performed and the product of interest
Figure 1
Exon-intron structure 3' of the VNTR that generates the secretory (A) and cell-associated (B) isoforms of MUC1. The letters 
'd' and 'a' refer to splice donor and acceptor sites. Bars represent translated sequence and lines represent non-coding mRNA 
(A) and removed introns (B). Sites of primer annealing and the sizes of predicted amplification products are indicated.Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/2
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excised from the gel and purified from the agarose slice us-
ing the Qiaex agarose gel extraction kit (Qiagen).
Restriction digestion and sequencing
Nco I (10 units at 5000 units/ml; Pharmacia Biotech) was
used in 1 × One-Phor-All Plus Buffer (10 mM Tris-acetate
pH 7.5, 10 mM magnesium acetate and 50 mM potassium
acetate). Sequencing of PCR Products was performed us-
ing a Sequenase Kit (United States Biochemical) as direct-
ed by the manufacturer.
Dual determinant Enzyme Linked Immunosorbant Assay 
(ELISA)
ELISAs were performed as previously described [3]. Brief-
ly, HPLC-purified BC2 (IgG) was employed as a capture
antibody and was coated on 96 well plates (Dynatech Im-
mulon) at a concentration of 4 µg/ml in PBS (pH 7.4),
100 µl/well for 4 h at room temperature. BC2 recognises
the repeating epitope PDTRP within the MUC1 VNTR do-
main. Non-specific sites were blocked with either PBS
containing 5% sucrose and 0.5% bovine serum albumin
(v/v), or 5% milk powder, 100 µl/well for 2 h at room
temperature. Wells were washed in 100 µl of PBS (pH 7.4)
containing 0.05% (v/v) Tween 20 (PBS-T) and 50 µl/well
of sample applied for an overnight incubation at 4°C. Af-
ter removal of sample, wells were washed in three 10 min
changes of PBS-T. In the conventional ELISA a second
anti-repeat McAb BC3 (IgM) was used as detector at 1/
1000 dilution of ascites in PBS. Alternatively, McAb
7H10/5 (IgM) raised against MUC1/SEC specific peptide
VSIGLSFPMLP [21], was used as detector at 1/1000 dilu-
tion of ascites in PBS. Incubation with 50 µl/well detector
antibody was performed for 2 h at room temperature and
followed by 3 × 10 min washes in PBS-T. Finally, a perox-
idase-conjugated rabbit anti-mouse IgM antibody (µ
chain specific; Nordic) was used at 1:500 in PBS, 50 µl/
well. After two 5 min washes in PBS-T and 5 min in citrate-
phosphate buffer (0.1 M citric acid, 0.1 M disodium hy-
drogen phosphate pH 5.0) 100 µl of substrate reagent 2
mM 2,2'azino-bis(3-ethylbenzthiazoline-6-sulfonic acid)
(ABTS; Boehringer Mannheim) containing 0.02% hydro-
gen peroxide in citrate phosphate buffer pH 5.0 was ap-
plied to the wells. Reaction product was measured by
absorbance at 405 nm in an automated plate reader (Bio-
Tek Instruments) after 20 min colour development. Neg-
ative controls were employed in which capture and detec-
tor antibodies were individually omitted from the assay,
together with the replacement of sample by PBS.
Immunofluorescence
Tissues were obtained at specific days of the luteal phase
monitored from the LH peak. Endometrial and tubal tis-
sue was snap-frozen in liquid nitrogen and 6 µm cryosec-
tions produced and stored at -80°. Sections were fixed in
cold methanol, 5 min, for anti-repeat MUC1 antibodies or
the unique epitope recognised by antibody 232A/1, which
is in the membrane-proximal domain of MUC1/REP/TM
[11]. The two monoclonal antibodies to MUC1/SEC did
not react with aldehyde-fixed (including routinely proc-
essed) or methanol-fixed tissue; for these reagents cold ac-
etone fixative was applied for 5 min, then sections treated
with PBS/4% BSA to block non-specific protein binding.
Carcinoma cell lines were cultured on multichamber glass
slides, while EEC were cultured in tissue culture plastic
wells. In each case fixation was with methanol. Staining
procedures as previously described [22]. First and second
antibodies were diluted in PBS/BSA. Controls carried out
with isotype-matched first antibodies were negative in all
cases.
Results
Identification of transcripts predicted to encode both cell-
associated and secretory isoforms of MUC1
Primers were designed to identify splice forms of MUC1
(Fig. 1). Primers 1 and 2 complementary to sequences in
exons 2 and 7 respectively were used to confirm the pres-
ence of the classical product MUC1/REP/TM from which
introns II to VI had been spliced out. (Fig. 1B). A single
product of the predicted size (752 bp) was produced from
cDNA prepared from normal endometrial tissue through-
out the menstrual cycle and also in cDNA from Ishikawa,
HEC1A and HEC1B endometrial carcinoma cells (not
shown). Restriction analysis was performed using Nco I,
which was predicted to cut at a single site at nucleotide
459. The 752 bp product yielded two fragments in the pre-
dicted size range of 274 bp and 459 bp.
A new 3' primer (Fig. 1A) was designed to anneal within
the 3' untranslated region (UTR) of the transcript predict-
ed to encode a truncated, secretory isoform of MUC1
(MUC1/SEC). The priming site lies within intron VI be-
tween exons 6 and 7 in the genomic sequence, and is
therefore unique to this transcript. Coupled with a 5'
primer that anneals at a site in exon 4 (Fig. 1A), this prim-
er was predicted to generate a PCR product of 686 bp. The
expected product was obtained using cDNA from en-
dometrium (Fig. 2A) or endometrial carcinoma cell lines
(Fig. 2B). Additional products were also generated, the
most abundant of which was 463 bp. Slight differences in
the relative abundance of products were observed, but no
obvious correlation was noted with the cycle stage of the
tissue from which the cDNA was derived.
The transcript predicted to encode MUC1/SEC is co-linear
with the gene. To discount the possibility of genomic
DNA contamination of total RNA, poly (A+) RNA was pu-
rified by two successive oligo d(T) column separations
and used in RT-PCR reactions. Identical products were
generated using cDNA derived from poly (A+) and total
RNA, confirming that these products were derived fromReproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/2
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Figure 2
Results of RT-PCR using primers 4 and 3 (see Fig. 1A) with: (A) 6 independent samples of secretory phase endometrial tissue 
cDNA. Lanes 1 and 2 are early, 3 and 4 mid, and 5 and 6 late secretory phase samples. Different patterns of product relative 
abundance were not found in particular phases. (B) RT-PCR using endometrial carcinoma cell lines HEC1A (1), HEC1B (2), 
AN3-CA (3) and the breast carcinoma cell line T47D (4). Controls in which cDNA was omitted were always negative (B, lane 
5). The 686 bp product is predicted to encode a secretory isoform of MUC1.
A
686
1       2        3    4       5       6
800
463
B
1      2       3      4 
800
686
463Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/2
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mRNA and not from genomic DNA (not shown). The
MUC1/SEC mRNA is predicted to be larger than that en-
coding normal MUC1. However we were unable to detect
abundant larger products on Northern blots using probes
either to the VNTR domain (Hey et al., 1994) or to SEC-
specific sequences (not shown). This suggests that the SEC
mRNA species is expressed at a lower level than trans-
membrane MUC1 mRNA.
The smaller product of 463 bp was re-amplified, purified
and sequenced in both directions. The sequence was in ac-
cord with the Genbank X52228 intron VI sequence except
t* for g and g* for a substitutions in the sequence aag ggt*
ccc tca ag*a ggg. This confirmed that it arose from a tran-
script that lacks introns II to V, but contains intron VI
sequence.
If translated, the transmembrane product encoded by this
novel spliced mRNA would harbour an extended cyto-
plasmic tail of 183 amino acids, the first 50 of which are
encoded by exon 6 and are identical to the conventional
C-tail. An additional novel sequence of 133 amino acids
could be encoded by the open reading frame of intron VI.
A polyclonal antiserum raised against a 17 amino acid
synthetic peptide representing the C-terminal residues of
the novel C-tail reacted strongly with the immunising
peptide but a native MUC1 protein could not be detected
either in endometrial carcinoma cell lines or tissue sec-
tions of endometrium. It could be that the polyclonal an-
tibody preparation directed against the synthetic peptide
does not recognise this epitope when presented in the
context of the putative native MUC1 protein. Alternative-
ly, the lack of immunoreactivity may indicate a low level
of transcription or translation. Further investigations will
be required to clarify whether this novel MUC1 protein is
indeed present.
Identification of MUC1/SEC protein in a double determi-
nant ELISA
Expression of the MUC1/SEC protein was examined using
two McAbs raised against the unique 11 mer peptide
(VSIGLSFPMLP) present at its C-terminus and corre-
sponding to the sequence encoded by intron II [21]. McAb
7H10/5 was used in combination with the anti-tandem
repeat McAb BC2 in a double determinant ELISA to deter-
mine whether the "soluble" form of MUC1 previously de-
tected in uterine flushings [3] is MUC1/SEC. Analysis of 8
secretory phase uterine flushings using the conventional
MUC1 ELISA (anti-VNTR capture and detector) confirmed
the presence of variable amounts of MUC1 in all samples
assayed (Fig. 3). Substitution of BC3 with the anti-MUC1/
SEC-specific McAb 7H10/5 revealed that a proportion of
the MUC1 signal is generated by MUC1/SEC protein.
Quantitative comparisons are not possible because anti-
VNTR detector antibodies can potentially bind to multiple
sites, whereas the anti-MUC1/SEC binds at a single
epitope. However, differences in the signal produced by
the two detector antibodies in different specimens suggest
that a proportion of the soluble MUC1 may be derived
from an isoform not detected by McAb 7H10/5.
Immunofluorescent detection of MUC1/SEC in epithelial 
cells
Initial experiments were carried out to ascertain optimal
conditions for the detection of MUC1/SEC in tissue sec-
tions. Negative results were obtained after fixation with al-
dehyde or alcohol, but strong immunofluorescence was
observed after fixation in acetone. This confirmed that
MUC1/SEC is present at the apical surface of both glandu-
lar and luminal epithelial cells in endometrium but ap-
pears more abundant in tubal tissue where the
distribution is again exclusively apical (Fig. 4). Similar re-
sults were obtained with the two different SEC-specific
monoclonal antibodies. MUC1/SEC co-distributes in tu-
bal tissue with transmembrane MUC1/REP/TM detected
using an antibody to the cytoplasmic tail (not shown).
Staining is present in the fimbrial (Fig. 4A,4B), ampullary
(Fig. 4C,4D) and isthmic (not shown) region of the tube
and appears to be associated with ciliated cells in all loca-
tions. Using the same specific fixation protocol, MUC1/
SEC is also associated with the surface of both primary
cultured endometrial epithelial cells (Fig. 5A) and HEC1B
cells (Fig. 5A,5B,5C,5D) where a heterogeneous distribu-
tion is apparent. A greater proportion of cells are immu-
nopositive when assayed with antibody BC3 to tandem
repeat sequences present in both MUC1/SEC and MUC1/
TM/REP, than with antibody to a unique MUC1/SEC de-
terminant (Fig. 5b,5c), indicating that some cells may
contain transmembrane MUC1 and not MUC1/SEC. An-
tibody 232A/1, which recognises a unique (non-repeat)
determinant on MUC1/TM/REP, binds a greater propor-
tion of cells than antibody 7H10/5 to MUC1/SEC (Fig.
5b,5d), suggesting that the transmembrane form may pre-
dominate in culture.
Discussion
MUC1 expression by endometrial glandular epithelium is
regulated during the menstrual cycle, with an increase in
abundance of full length, VNTR-containing mRNA and
protein (MUC/TM/REP) during the post-ovulatory, secre-
tory phase [6]. MUC1 immunoreactivity is associated with
the apical epithelial cell surface of glandular and luminal
epithelial cells in both proliferative and secretory phases
[3,6]. In the mid-secretory phase, levels of soluble MUC1
begin to increase in uterine fluid [3]. Here we have de-
vised a reverse transcriptase PCR strategy that confirms the
presence of the transmembrane isoform MUC1/TM/REP
and indicates the existence of an alternative splicing
mechanism that accounts for the production of an iso-
form MUC1/SEC that lacks the transmembrane andReproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/2
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intracellular domains. Further, we have investigated these
different isoforms of MUC1 in normal endometrium and
Fallopian tube, and in endometrial carcinoma cell lines.
A transcript predicted to encode MUC1/SEC was identi-
fied in endometrial cDNA from across the menstrual cycle
and also in a variety of cell lines. The results of RT-PCR
were confirmed by the use of two McAbs that recognise an
11 amino acid sequence unique to MUC1/SEC [21]. A
double determinant ELISA enabled the detection of TR-
containing MUC1/SEC molecules in secretory phase uter-
ine flushings. MUC1/SEC protein has also been detected
immunochemically in sera of breast cancer patients and
in medium conditioned by T47D breast cancer cells [18]
suggesting that it might account for the secreted MUC1
observed in tissue sections and uterine fluid [6]. Immun-
ofluorescence also reveals MUC1/SEC in gland secretions.
However, variation in the signal generated in uterine
flushings by MUC1/SEC relative to that from the conven-
tional anti-TR ELISA suggests that secreted MUC1 may not
comprise exclusively MUC1/SEC. Proteolytic cleavage of
surface-associated MUC1 has been postulated as an alter-
native mechanism of release [2].
In immunofluorescence, MUC1/SEC is readily detectable
in association with the apical surface of endometrial epi-
thelial cells. It is also displayed at the surface of tubal epi-
thelial cells in vivo, and in vitro on primary endometrial
epithelial cells and HEC1B cells. MUC1/SEC is known to
bind with high affinity to another isoform, MUC1/Y,
which arises from the same gene by another splicing path-
way [23]. We have evidence for the presence of the MUC1/
Y mRNA in endometrium [3]. The apical surface expres-
sion of MUC1/SEC may be accounted for by the presence
of MUC1/Y in the plasma membrane, though further ex-
periments will be required to verify this hypothesis.
Figure 3
Analysis of uterine flushings using a double determinant ELISA. Anti-VNTR McAb BC2 was used as capture antibody with 
either anti-VNTR McAb BC3 (white bars) or anti-MUC1/SEC McAb 7H10/5 (grey bars) as detector antibodies. Use of 7H10/5 
results in the identification VNTR-containing MUC1/SEC species, thus confirming expression of the alternatively spliced secre-
tory isoform in endometrium. The vertical axis represents absorbance at 405 nm. Individual controls in which capture, uterine 
flushings and detector antibodies were omitted from the assay were performed for each antibody. For BC3 the mean control 
absorbance values obtained was 0.172 (sd = 0.0408) and for 7H10/5 was 0.316 (sd = 0.145).
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Figure 4
Immunofluorescence (A,C,E,G) and matching phase contrast (B,D,F,H) micrographs of (A,B) tubal (fimbrial) tissue (luteal phase 
day 3), (C,D) tubal (ampullary) tissue (luteal phase day 8) and (E-H) mid secretory endometrium (luteal phase day 8) stained 
with McAb 7H10/5. The antibody recognises the unique C-terminal peptide of MUC1/SEC. The interrupted pattern of staining 
in the tubal epithelium (A,C) reflects an association with ciliated cells. Staining is apparent at the apical surface of both luminal 
(E) and glandular (G) endometrial epithelium, and is also associated with secretory material.
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The apical surface expression of different MUC1 gene
products in the upper reproductive tract suggests the pos-
sibility of a role in relation to embryo transport and
implantation. High levels of MUC1 at the cell surface re-
duce cell-cell and cell-matrix interactions, probably
through steric hindrance [24,25]. This could create a bar-
rier to embryo implantation, and thus help explain the
non-receptivity of normal tubal tissue as well as the ina-
bility of donor embryos when transferred to the uterine
cavity at inappropriate cycle times [26,27]. Further evi-
dence for the role of MUC1 as a barrier component is pro-
vided by the observation that mouse embryos attach more
readily to epithelial cells from Muc1-null mice [28]. In a
primate model where ectopic implantation is unknown,
we observed MUC1/SEC in tubal epithelium but not in
the uterus, indicating the possibility of a greater barrier to
attachment at the tubal surface [29]. Rabbit endometri-
um, like human, has a high level of MUC1 expression at
the surface in early pregnancy, but this is down-regulated
in the implantation site, probably as a result of paracrine
signals from the embryo [30]. Local removal of MUC1 is
predicted to allow receptor-mediated cell-cell interaction
to proceed between the trophectoderm and the maternal
epithelium, attaching the embryo to the apical epithelial
cell surface in the first stage of implantation. This may oc-
cur by means of an apical surface reorganisation with the
appearance of pinopods (also known as uterodomes [31])
that have been reported to lack MUC1 immunoreactivity
[32]. Observations from an in vitro model of human im-
plantation also suggest that a signal from the embryo may
stimulate local loss of MUC1 at the site of implantation
[33]. Results presented in the current study suggest a hy-
Figure 5
Immunofluorescence of primary cultured endometrial epithelial cells (A) and HEC1B cells (B-D) stained with antibodies against 
MUC1/SEC (A,B; Mab 7H10/5)), MUC1 tandem repeat domain (C; Mab BC3)) and a unique determinant in the ectodomain (D; 
Mab 232A/1). All fields contain confluent cells and the staining in each case is heterogeneous. The cell surface association of 
MUC1/SEC is particularly obvious in B.
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pothesis that removal of cell surface-associated MUC1/
SEC as well as transmembrane MUC1 is required in order
to permit implantation. They also suggest that receptivity
might be defined as the ability of a steroidally-sensitised
epithelium to respond to an embryonic stimulus; this
ability is predicted to differ between tubal and endometri-
al locations.
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